AMNEAL PHARMACEUTICALS, INC. Revenue
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Revenue of $796.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $796.20M, a 9.89% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $722.52M, a 3.90% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $814.32M, a 11.47% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $784.51M, a 11.68% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $3.02B, a 8.05% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $2.79B, a 16.73% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.39B, a 8.20% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $2.21B, a 5.67% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $796.20M 10-Q · filed 2026-08-06 | $1.52B 10-Q · filed 2026-08-06 | $2.33B derived: sum of 3 quarters · filed 2026-08-06 | $3.12B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $722.52M 10-Q · filed 2026-05-07 | $1.54B derived: sum of 2 quarters · filed 2026-05-07 | $2.32B derived: sum of 3 quarters · filed 2026-05-07 | $3.05B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $814.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.60B derived: sum of 2 quarters · filed 2026-02-27 | $2.32B derived: sum of 3 quarters · filed 2026-08-06 | $3.02B 10-K · filed 2026-02-27 |
| 2025-09-30 | $784.51M 10-Q · filed 2025-11-06 | $1.51B derived: sum of 2 quarters · filed 2026-08-06 | $2.20B 10-Q · filed 2025-11-06 | $2.93B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $724.51M 10-Q · filed 2026-08-06 | $1.42B 10-Q · filed 2026-08-06 | $2.15B derived: sum of 3 quarters · filed 2026-08-06 | $2.85B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $695.42M 10-Q · filed 2026-05-07 | $1.43B derived: sum of 2 quarters · filed 2026-05-07 | $2.13B derived: sum of 3 quarters · filed 2026-05-07 | $2.83B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $730.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.43B derived: sum of 2 quarters · filed 2026-02-27 | $2.13B derived: sum of 3 quarters · filed 2026-02-27 | $2.79B 10-K · filed 2026-02-27 |
| 2024-09-30 | $702.47M 10-Q · filed 2025-11-06 | $1.40B derived: sum of 2 quarters · filed 2025-11-06 | $2.06B 10-Q · filed 2025-11-06 | $2.68B derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $701.78M 10-Q · filed 2025-08-07 | $1.36B 10-Q · filed 2025-08-07 | $1.98B derived: sum of 3 quarters · filed 2026-02-27 | $2.60B derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $659.19M 10-Q · filed 2025-05-07 | $1.28B derived: sum of 2 quarters · filed 2026-02-27 | $1.90B derived: sum of 3 quarters · filed 2026-02-27 | $2.50B derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $616.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.24B derived: sum of 2 quarters · filed 2026-02-27 | $1.84B derived: sum of 3 quarters · filed 2026-02-27 | $2.39B 10-K · filed 2026-02-27 |
| 2023-09-30 | $620.04M 10-Q · filed 2024-11-12 | $1.22B derived: sum of 2 quarters · filed 2024-11-12 | $1.78B 10-Q · filed 2024-11-12 | $2.39B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $599.05M 10-Q · filed 2024-08-09 | $1.16B 10-Q · filed 2024-08-09 | $1.77B derived: sum of 3 quarters · filed 2025-02-28 | $2.31B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $557.54M 10-Q · filed 2024-05-08 | $1.17B derived: sum of 2 quarters · filed 2025-02-28 | $1.71B derived: sum of 3 quarters · filed 2025-02-28 | $2.27B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $609.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.16B derived: sum of 2 quarters · filed 2025-02-28 | $1.71B derived: sum of 3 quarters · filed 2025-02-28 | $2.21B 10-K · filed 2025-02-28 |
| 2022-09-30 | $545.56M 10-Q · filed 2023-11-09 | $1.10B derived: sum of 2 quarters · filed 2023-11-09 | $1.60B 10-Q · filed 2023-11-09 | $2.14B derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $559.36M 10-Q · filed 2023-08-08 | $1.06B 10-Q · filed 2023-08-08 | $1.59B derived: sum of 3 quarters · filed 2024-03-14 | $2.12B derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $497.63M 10-Q · filed 2023-05-09 | $1.03B derived: sum of 2 quarters · filed 2024-03-14 | $1.56B derived: sum of 3 quarters · filed 2024-03-14 | $2.10B derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $536.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.07B derived: sum of 2 quarters · filed 2024-03-14 | $1.60B derived: sum of 3 quarters · filed 2024-03-14 | $2.09B 10-K · filed 2024-03-14 |
| 2021-09-30 | $528.59M 10-Q · filed 2022-11-07 | $1.06B derived: sum of 2 quarters · filed 2022-11-07 | $1.56B 10-Q · filed 2022-11-07 | $2.07B derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $535.08M 10-Q · filed 2022-08-08 | $1.03B 10-Q · filed 2022-08-08 | $1.54B derived: sum of 3 quarters · filed 2023-03-03 | $2.06B derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $493.11M 10-Q · filed 2022-05-06 | $1.00B derived: sum of 2 quarters · filed 2023-03-03 | $1.52B derived: sum of 3 quarters · filed 2023-03-03 | $1.99B derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $510.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $1.03B derived: sum of 2 quarters · filed 2023-03-03 | $1.49B derived: sum of 3 quarters · filed 2023-03-03 | $1.99B 10-K · filed 2023-03-03 |
| 2020-09-30 | $519.29M 10-Q · filed 2021-11-08 | $983.96M derived: sum of 2 quarters · filed 2021-11-08 | $1.48B 10-Q · filed 2021-11-08 | $1.88B derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $464.66M 10-Q · filed 2021-08-09 | $963.20M 10-Q · filed 2021-08-09 | $1.36B derived: sum of 3 quarters · filed 2021-08-09 | $1.74B derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $498.53M 10-Q · filed 2021-05-07 | $895.86M derived: sum of 2 quarters · filed 2021-05-07 | $1.27B derived: sum of 3 quarters · filed 2021-05-07 | $1.68B derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $397.33M 10-K · filed 2020-03-02 | $775.61M derived: sum of 2 quarters · filed 2020-11-06 | $1.18B derived: sum of 3 quarters · filed 2020-11-06 | $1.63B 10-K · filed 2022-03-01 |
| 2019-09-30 | $378.28M 10-Q · filed 2020-11-06 | $782.92M derived: sum of 2 quarters · filed 2020-11-06 | $1.23B 10-Q · filed 2020-11-06 | $1.73B derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | $404.64M 10-Q · filed 2020-08-06 | $850.76M 10-Q · filed 2020-08-06 | $1.35B derived: sum of 3 quarters · filed 2020-08-06 | $1.82B derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $446.12M 10-Q · filed 2020-05-11 | $943.65M derived: sum of 2 quarters · filed 2020-05-11 | $1.42B derived: sum of 3 quarters · filed 2020-05-11 | $1.83B derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $497.53M 10-K · filed 2020-03-02 | $974.01M derived: sum of 2 quarters · filed 2020-03-02 | $1.39B derived: sum of 3 quarters · filed 2020-03-02 | $1.66B 10-K · filed 2021-03-01 |
| 2018-09-30 | $476.49M 10-K · filed 2020-03-02 | $890.27M derived: sum of 2 quarters · filed 2020-03-02 | $1.17B 10-Q · filed 2019-11-07 | $1.46B derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $413.79M 10-K · filed 2020-03-02 | $688.98M 10-Q · filed 2019-08-05 | $982.35M derived: sum of 3 quarters · filed 2020-03-02 | $1.24B derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $275.19M 10-K · filed 2020-03-02 | $568.56M derived: sum of 2 quarters · filed 2020-03-02 | $823.29M derived: sum of 3 quarters · filed 2020-03-02 | $1.08B derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $293.37M 10-K · filed 2019-03-01 | $548.10M derived: sum of 2 quarters · filed 2019-03-01 | $807.97M derived: sum of 3 quarters · filed 2019-03-01 | $1.03B 10-K · filed 2020-03-02 |
| 2017-09-30 | $254.73M 10-K · filed 2019-03-01 | $514.60M derived: sum of 2 quarters · filed 2019-03-01 | $740.28M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $259.87M 10-K · filed 2019-03-01 | $485.55M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $225.68M 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $1.02B 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |